Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. It researches, develops translational science, new-drug molecular design, and screening technology for the treatment of cancer, immunological diseases, and chronic kidney diseases. The company was founded by Xiao Lin Zhang on October 27, 2017 and is headquartered in Shanghai, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company